Clinical Trials on Usher Syndrome, Type 1B in New Zealand

Total 615 results

National Eye Institute (NEI)

Completed

Natural History and Genetic Studies of Usher Syndrome

Retinitis Pigmentosa | Usher Syndrome | Retinitis Pigmentosa Syndromic | Congenital Deafness | Retinitis Pigmentosa and Deafness

United States
ProQR Therapeutics

Active, not recruiting

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, Netherlands, United Kingdom, Germany
National Center for Research Resources (NCRR)

Completed

A Genetic Analysis of Usher Syndrome in Ashkenazi Jews

Retinitis Pigmentosa | Usher Syndrome | Congenital Hearing Impairment

United States
Zhejiang Doer Biologics Co., Ltd.

Recruiting

A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624

Healthy, Obesity, Metabolically

New Zealand
Otsuka Australia Pharmaceutical Pty Ltd

Recruiting

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia (PREFER-HMA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Patient Preference

New Zealand, Australia
Hospital for Special Surgery, New York

Not yet recruiting

Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome (LDN-CRPS)

Chronic Pain | Complex Regional Pain Syndrome | Causalgia | Complex Regional Pain Syndrome Type I | Complex Regional Pain Syndrome Type II

United States
Memorial Sloan Kettering Cancer Center

Completed

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Advanced Myelodysplastic Syndromes

United States
State University of New York - Upstate Medical...
Reflex Sympathetic Dystrophy Syndrome Association (RSDSA)

Recruiting

rTMS and Rehabilitation for Individuals With CRPS Type 1

Complex Regional Pain Syndrome Type I

United States
National Cancer Institute (NCI)

Completed

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Disease | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States, Canada, New Zealand
Weill Medical College of Cornell University
Jazz Pharmaceuticals

Completed

CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Relapsed Adult Acute Myeloid | Myelodysplastic Syndromes, Previously Treated

United States
Memorial Sloan Kettering Cancer Center

Completed

Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse

Myelodysplastic Syndromes (MDS) | Acute Myelogenous Leukemia (AML)

United States
Ruhr University of Bochum

Unknown

Effects of Repetitive Electric Sensory Stimulation (RSS) as Intervention in Complex-regional-pain-syndrome Type I (CRPS)

Complex Regional Pain Syndrome Type I of the Upper Limb

Germany
Millennium Pharmaceuticals, Inc.

Completed

A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome

Acute Myelogenous Leukemia | High-Grade Myelodysplastic Syndrome

United States
Viron Therapeutics Inc
Vion Pharmaceuticals

Terminated

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Mirati Therapeutics Inc.

Completed

A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
Cornerstone Pharmaceuticals

Withdrawn

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Onconova Therapeutics, Inc.

Completed

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia

United States
Weill Medical College of Cornell University

Completed

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

Canada, United States
Remix Therapeutics

Not yet recruiting

Study of REM-422 in Patients With AML or Higher Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Myeloid Leukemia Refractory | Higher Risk Myelodysplastic Syndromes

United States
Weill Medical College of Cornell University
New York Blood Center

Terminated

IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
University of Rochester

Active, not recruiting

A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Vor Biopharma

Recruiting

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Canada
Celgene

Terminated

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Arrowhead Pharmaceuticals

Completed

Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

Hypertriglyceridemia | Familial Chylomicronemia

Australia, Canada, New Zealand
Hoffmann-La Roche

Completed

A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Aptose Biosciences Inc.

Active, not recruiting

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Myelodysplastic Syndromes | Leukemia

United States
Dartmouth-Hitchcock Medical Center
Millennium Pharmaceuticals, Inc.

Completed

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

United States
Aprea Therapeutics

Completed

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia or Myelodysplastic Syndromes

United States
Celgene

Completed

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, United Kingdom
University of Rochester

Completed

A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
NYU Langone Health

Terminated

AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibroses

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
The Canadian Blood and Marrow Transplant Group
National Cancer Institute (NCI)

Completed

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Graft Versus Host Disease | Secondary Myelofibrosis

Australia, Canada, United States, New Zealand, Saudi Arabia
Edgewood Oncology Inc.

Recruiting

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Novartis Pharmaceuticals

Completed

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Cyclacel Pharmaceuticals, Inc.
M.D. Anderson Cancer Center

Unknown

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Weill Medical College of Cornell University

Completed

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

Myelodysplastic Syndromes | Leukemia, Erythroblastic, Acute

United States
NYU Langone Health

Completed

Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi

Dysplastic Nevi

United States
Memorial Sloan Kettering Cancer Center

Terminated

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Acute Leukemia | Myelodysplastic Syndrome | Non-Hodgkins Lymphoma | Chronic Leukemia

United States
University of Rochester

Recruiting

Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome (MRD)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Weill Medical College of Cornell University
Jazz Pharmaceuticals

Completed

A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Anemia | Chronic Myelomonocytic Leukemia | Adult Myelodysplastic Syndrome

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Neutropenia

United States
Astex Pharmaceuticals, Inc.

Recruiting

A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelocytic Leukemia | Myelodysplastic Syndrome/Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States

Clinical Trials on Usher Syndrome, Type 1B in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations